Krystal Biotech KRYS
First Signal's file · in 2 issues · All companies
Gene therapy for a rare skin disease
Every time it made the issue
We cover a company only when it moves enough to matter. Each row is one of those days, what we made of it, and how the stock did over the next 5 and 20 trading days, next to the S&P 500.
| Date | Where | Move | Our read | 5 days later | 20 days later |
|---|---|---|---|---|---|
| Mon, Nov 2, 2026 | Earnings | −11.0% | Sales of Vyjuvek rose 30%, but results from three trials slip into 2027. | to come | to come |
| Mon, Nov 2, 2026 | Earnings | −14.3% | Sales of Vyjuvek rose 30% to $127.3 million, but three of its trials are running late, with results pushed into 2027. | to come | to come |
Its biggest days since September 2017
| Best days | Move |
|---|---|
| Mon, Nov 29, 2021 | +121.7% |
| Mon, Jun 24, 2019 | +41.3% |
| Mon, Feb 26, 2024 | +41.0% |
| Worst days | Move |
|---|---|
| Thu, Mar 12, 2020 | −22.9% |
| Mon, Nov 22, 2021 | −19.6% |
| Mon, Nov 6, 2023 | −15.0% |
How it took its last 8 reports
The stock's move in the first session after each quarterly report. Next report: not yet announced.
| Results filed | Next session |
|---|---|
| Mon, Nov 2, 2026 | −11.0% |
| Mon, Aug 3, 2026 | −8.4% |
| Tue, Feb 17, 2026 | +4.1% |
| Mon, Nov 3, 2025 | +0.2% |
| Mon, Aug 4, 2025 | −14.0% |
| Tue, May 6, 2025 | −14.1% |
| Mon, Nov 4, 2024 | −3.1% |
| Mon, Aug 5, 2024 | −5.9% |
Moves are daily closing prices. Past moves don't predict future ones.
